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INTRODUCTION
Lung cancer is the leading cause of cancer-related deaths in
the world, and non-small cell lung cancer (NSCLC) accounts
for nearly 80% of the disease (1). The clinicopathologic stag-
ing system has been the standard for determining lung can-
cer treatment, but it includes heterogenous groups of patients
within one stage (2). Nearly 25-80% of NSCLC patients ex-
perience recurrences and they have poor prognosis despite
curative resection (3, 4). 
Adjuvant therapy after surgery has shown a survival ben-
efit for the stage II to IIIA groups, but not for the stage I
group (5, 6). Thus, we need to select those patients who can
achieve a real survival advantage as weighted against the risk
of undergoing adjuvant cytotoxic chemotherapy. In the treat-
ment of NSCLC, in order to achieve more highly selective
treatment especially for the high-risk patients for recurrence
and to reduce unnecessary toxic treatment to the low-risk
patients, we need the ability to predict the surgical outcome
of an individual patient. Recent studies have focused on the
identification of risk factors that influence postoperative sur-
vival and recurrence in a large group of patients, and multi-
ple factors have been proposed, which were not only clinical
factors but also biologic markers and gene-expression profiles
using microarray (7-9). However, these risk factors could not
be applicable to each patient, and any single, definite factor
has failed to explain the prognosis. Thereafter, we considered
a prediction model using multiple clinical factors, which can
be applicable to individual patients at the bedside. 
We especially evaluated the early recurrence within one
year after surgery and purposed to evaluate the predictabili-
ty and to find out the limitations of retrospective clinical in-
formation.
MATERIALS AND METHODS
Patients
Our Institutional Review Board approved this study and
waived the requirement for individual patient consent (IRB
No. 2006-12-038). From 1994 to 2004, a total of 1,640 pa-
tients underwent pulmonary resections for the treatment of
NSCLC at the Samsung Medical Center in Korea. In every
case, after mediastinal nodal staging using a mediastinoscop-
ic biopsy, we performed curative resection and lymph nodes
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Predicting Recurrence Using the Clinical Factors of Patients with
Non-small Cell Lung Cancer After Curative Resection
We present a recurrence prediction model using multiple clinical parameters in pa-
tients surgically treated for non-small cell lung cancer. Among 1,578 lung cancer
patients who underwent complete resection, we compared the early-recurrence
group with the 3-yr non-recurrence group for evaluating those factors that influence
early recurrence within one year after surgery. Adenocarcinoma and squamous
cell carcinoma were analyzed independently. We used multiple logistic regression
analysis to identify the independent clinical predictors of recurrence and Cox’s pro-
portional hazard regression method to develop a clinical prediction model. We ran-
domly divided our patients into the training and test subsets. The pathologic stages,
tumor cell type, differentiation of tumor, neoadjuvant therapy and age were signifi-
cant factors on the multivariable analysis. We constructed the model for the train-
ing set with adenocarcinoma (n=236) and squamous cell carcinoma (n=305), and
we applied it to the test set with adenocarcinoma (n=110) and squamous cell car-
cinoma (n=154). It was predictive for the in adenocarcinoma (P<0.001) and the
squamous cell carcinoma (P=0.037), respectively. Our results showed that our
recurrence prediction model based on the clinical parameters could significantly
predict the individual patients who were at high risk or low risk for recurrence.
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dissection. If mediastinal nodal metastasis was detected from
the mediastinoscopic result, then neoadjuvant concurrent
chemo-radiation therapy followed. After surgery, patients
were regularly followed-up. We scheduled the performance
of clinical reevaluations two weeks after surgery and then every
three months for the first two years, every six months for the
next three years, and once every year thereafter. Each follow-
up visit was supplemented by chest radiography. A restag-
ing evaluation including chest computed tomography per-
formed at diagnosis was scheduled in all subjects six months
after their operation. Recurrence was defined as any unequiv-
ocal occurrence of new cancer foci in a disease-free patient
and included all patterns of recurrences (local, regional, and
distant). We defined early tumor recurrence as a tumor relapse
that occurred within one year of the operation. This cut-off
time was clearly an arbitrary one, which we chose based on
biological considerations and after a preliminary inspection
of our database. Among 1,640 patients, sixty-two patients
(3.8%) experienced operative mortality (operative mortality
was defined to include all deaths directly related to the sur-
gical procedures regardless of time of occurrence, within thir-
ty days or after thirty days, and of type of hospitalization, in-
trahospital or extrahospital), and they were excluded from
analysis. Therefore, we retrospectively reviewed the charts
and radiological findings of 1,578 NSCLC patients and con-
tacted the patients and their families to gather recent infor-
mation. Clinical variables such as age, gender, pathologic
TNM stage, cell type, differentiation, neoadjuvant therapy,
adjuvant therapy, presence or absence of double primary malig-
nancies, and completeness of resection were selected for the
consideration of recurrence (Table 1).
Overall and subgroups description
After we analyzed and performed a predictive model using
all the data from 1,578 patients, we classified it into recurred
patients and non-recurred patients to evaluate recurrence-pre-
dicting factors more definitely. We defined the early recur-
rence group as patients who had recurred diseases detected
within one year postoperatively and the non-recurrence group
as the survivors who were recurrence-free more than three
years after curative surgery (Fig. 1). Histology was limited
to adenocarcinoma (ADC, n=346) and squamous cell carci-
noma (SQC, n=459). There were 349 patients (169 in ADC,
180 in SQC) in the early-recurrence group and 456 (177 in
ADC, 279 in SQC) in the non-recurrence group.
Variables
No. of subjects
(n=1,578)
Gender
Male 1,217 (77.1%)
Female 361 (22.9%)
Age (yr) 61.1±9.5 (13-83)
Tumor size (cm) 3.9±2.1 (0.2-20)
Histology
Squamous 765 (48.5%)
Adenocarcinoma 668 (42.3%)
Bronchioloalveolar 48 (3.0%)
Large cell 80 (5.1%)
Adenosquamous 17 (1.1%)
Type of resection
Pneumonectomy 239 (15.2%)
Bilobectomy 171 (10.8%)
Lobectomy 1,154 (73.1%)
Limited resection 14 (0.9%)
Pathologic stage
I 835 (53.0%)
II 308 (19.6%)
III 376 (23.8%)
IV 44 (2.8%)
Neoadjuvant treatment 178 (11.3%)
Adjuvant treatment 438 (27.8%)
Differentiation
Well 216  (13.7%)
Moderately 799 (50.6%)
Poorly 282 (17.9%)
Unknown 281(17.8%)
Double primary disease 117 (7.4%)
Follow-up period (months) 40.1±28.1 (0.6-139.3)
Recurrence 742 (47.0%)
Cancer related Death 527 (33.4%)
Table 1. Clinicopathologic characteristics of the all 1,578 pati-
ents with non-small cell lung cancer and who underwent com-
plete resection 
1 yr
Recurrence
(n=688)
349
34
88
456
251
255
Non-recurrence
(n=745)
No. (ADC+SQC)=1,433 Recurrence-free survival
3 yr 5 yr
�
*
Fig. 1. This shows subgroups
of patients. Among 1,578 pati-
ents, 1,433 patients had ade-
nocarcinoma or squamous cell
carcinoma, and 688 patients
were detected recurred disease
during follow-up period. 
*, The early recurrence group is defined as patients who had recurred diseases detected within one year posteperatively; 
� , The non-recurrence
group is defined as the survivors who were recurrence-free more than three years after curative surgery.826 H.J. Lee, J. Jo, D.-S. Son, et al.
Statistical analysis and modeling procedure
We first performed univariate and multivariate analysis for
the clinical factors affecting recurrence. The statistical algo-
rithm for the recurrence prediction model is constituted by
Cox’s proportional hazard regression model using a stepwise
variable selection method that takes into consideration clini-
cal factors that affect the time to recurrence such as age, gender,
cell type, pathological stage, differentiation, and curative resec-
tion. All clinical characteristics were considered in a multiple
Cox model to determine which demonstrated the strongest
associations with recurrence. The clinical parameters other than
age were applied without modification as the categorical data.
When the hazard ratio calculated by Cox’s proportional haz-
ard model was greater than 1.0, the patients were classified as
belonging to the high-risk group for early recurrence, and when
the hazard ratio was smaller than 1.0, they were classified as
belonging to the low-risk group (10). A log-rank test was car-
ried out to compare the survival rates of the two risk groups.
For constructing the model, 346 ADC patients and 459 SQC
patients were divided into a 2:1 ratio between the training
sets (236 in the ADC group, and 305 in the SQC group) and
the test sets (110 in the ADC group, and 154 in the SQC
group). Each group was stratified by random sampling to
CI, confidence interval.
Multivariate analysis
Variables
Hazard ratio 95% CI P value
Univariate analysis
Hazard ratio 95% CI P value
Age 1.007 (1.000, 1.015) 0.066 1.019 (1.011, 1.028) <0.001
Gender 0.429 0.713
Male 1.000 1.000
Female 0.934 (0.788, 1.107) 0.964 (0.793, 1.173)
Pathologic stage <0.001 <0.001
T stage
T1 1.000 1.000
T2 1.376 (1.135, 1.668) 1.322 (1.084, 1.612)
T3 3.725 (2.886, 4.808) 3.419 (2.618, 4.466)
T4 2.495 (1.899, 3.280) 1.953 (1.468, 2.597)
N stage <0.001 <0.001
N0 1.000 1.000
N1 2.043 (1.706, 2.448) 2.035 (1.679, 2.467)
N2 2.845 (2.389, 3.387) 2.404 (1.954, 2.957)
M stage <0.001 <0.001
M0 1.000 1.000
M1 2.734 (1.895, 3.943) 2.224 (1.528, 3.238)
Cell type <0.001 <0.001
Squamous 1.000 1.000
Adenocarcinoma 1.289 (1.110, 1.498) 1.428 (1.200, 1.699)
Bronchioloalveolar 0.248 (0.117, 0.524) 0.520 (0.234, 1.155)
Large cell 1.301 (0.930, 1.820) 1.654 (1.119, 2.443)
Adenosquamous 1.488 (0.767, 2.886) 1.452 (0.727, 2.898)
Differentiation <0.001 0.008
Well 1.000 1.000
Moderately 1.428 (1.131, 1.804) 1.273 (1.001, 1.618)
Poorly 2.102 (1.622, 2.724) 1.567 (1.195, 2.056)
Curative resection 0.092 0.260
R0 1.000 1.000
R1 0.855 (0.528, 1.383) 0.854 (0.526, 1.385)
R2 1.953 (0.810, 4.707) 1.992 (0.810, 4.899)
Neoadjuvant <0.001 <0.001
None 1.000 1.000
Done 1.894 (1.551, 2.311) 1.638 (1.311, 2.046)
Adjuvant <0.001 0.394
None 1.000 1.000
Done 1.738 (1.494, 2.022) 0.926 (0.775, 1.106)
Double primary 0.393 0.477
No 1.000 1.000
Yes 0.887 (0.674, 1.168) 0.903 (0.682, 1.196)
Table 2. Univariate and multivariate analyses of 1,578 patients using Cox’s proportional hazard regression model Predicting Recurrence in Operated Non-small Cell Lung Cancer Patients 827
equally distribute all the clinical parameters; models were con-
structed with the training sets, and applied to the test sets.
To evaluate the performance of the models, we applied the
Kaplan-Meier survival curve and the log-rank test between the
risk groups, where 5% was accepted as the significance level. 
RESULTS
The patients’ overall analyses
In this study, we retrospectively analyzed 1,578 patients,
who were followed-up at the outpatient clinic after curative
lung cancer surgery. The clinical information is listed in Table
1. There were 1,217 men (77.1%), and the mean age of the
patients was 61.1 yr (SD, 9.5 yr). The most common histo-
pathologic type was SQC (48.5%), and ADC was the next
most common (42.3%). Most patients underwent complete
resection at the first surgery (96.8%). During a mean of 40.1
months (SD, 28.1 months) for the follow-up period, 742 pa-
tients (47.0%) were diagnosed with recurred diseases, and
349 (47.0%) among them were detected within one year of
surgery. During the same period, 527 patients (33.4%) died
of cancer-related causes. Before the modeling process, we ana-
lyzed the significant factors influencing recurrence. Univari-
ate analysis of the relationship between recurrence and the
clinical parameters showed statistically significant for advanced
TNM stage (P<0.001, respectively), cell type (P<0.001),
differentiation (P<0.001), undergoing neoadjuvant therapy
(P<0.001), and adjuvant therapy (P<0.001) (Table 2). Mul-
tivariate analysis revealed that age (P<0.001), TNM stage
(P<0.001, respectively), cell type (P<0.001), differentiation
(P<0.007), and neoadjuvant therapy (P<0.001) were related
to the recurrence (Table 2).
Subgroup analyses according to recurrence and histology
Among the total 1,578 patients, there were 349 (22.1%)
in the early-recurrence group and 456 (28.9%) in the non-
recurrence group, and the early-recurrence group could be
further divided with 169 in ADC and 180 in SQC (25.3%
vs. 23.5%; ratio to total patients in each cell type). Table 3
shows patients’ characteristics for each cell type. There were
more male patients in SQC than in ADC. The significant clini-
cal factors associated with recurrence on the univariate and
multivariate analyses agreed with those of the total patients.
There were 346 ADC patients (of whom 169 belonged to
the early recurrence subset and 177 belonged to the subset
showing non-recurrence after more than 3 yr). We performed
a Cox’s model with a training group of 236 and then evalu-
ated the model by applying it to a test group of 110. Stage
factors (tumor and nodal factors) and tumor differentiation
were finally entered into the model as possible predictive fac-
tors (as demonstrated in Table 4). Test group patients were
divided into two risk groups (high- and low-risk) using 1.0
as cut-off value with statistically significant results (where
the P value is less than 0.001 in the log-rank test). Fig. 2-1
is the Kaplan-Meier curve for the recurrence-free survival
Variables
Adenocarcinoma
(n=346)
Squamous
(n=459)
P value
Gender <0.001
Male 219 (63.3%) 437 (95.2%)
Female 127 (36.7%) 22 (4.8%)
Age (yr) 59.1±10.5 61.7±8.4 <0.001
(13-83) (37-82)
Tumor size (cm) 3.7±2.3 4.3±2.2 0.001
(0.4-20) (0.2-16)
Type of resection <0.001
Pneumonectomy 29 (8.4%) 122 (26.6%)
Bilobectomy 26 (7.5%) 68 (14.8%)
Lobectomy 288 (83.2%) 268 (58.4%)
Limited resection 3 (0.9%) 1 (0.2%)
Pathologic stage <0.001
I 180 (52.0%) 238 (51.9%)
II 47 (13.6%) 106 (23.1%)
III 102 (29.5%) 97 (21.1%)
IV 17 (4.9%) 10 (2.2%)
Neoadjuvant treatment 45 (13.0%) 56 (12.2%) 0.733
Adjuvant treatment 106 (30.6%) 119 (25.9%) 0.140
Differentiation <0.001
Well  63 (18.2%) 53 (11.5%)
Moderately 136 (39.3%) 293 (63.8%)
Poorly 102 (29.5%) 69 (15.0%)
Unknown 45 (13.0%) 44 (9.6%)
Double primary disease 23 (6.6%) 34 (7.4%) 0.677
Follow-up period (months) 41.6±30.0 47.0±32.8 0.014
(1.5-138.1) (1.5-139.3)
Recurrence 169 (48.8%) 180 (39.2%) 0.006
Cancer related Death 124 (35.8%) 148 (32.2%) 0.286
Table 3. Clinicopathologic information of the patients with early
recurrence and those with three years non-recurrence for each
histological type 
Variables Hazard ratio 95% CI P value
T stage <0.001
T1 1.000
T2 1.826 (1.073, 3.106)
T3 3.478 (1.894, 6.386)
T4 1.594 (0.739, 3.439)
N stage <0.001
N0 1.000
N1 2.511 (1.505, 4.189)
N2 3.381 (2.194, 5.209)
Differentiation 0.024
Well 1.000
Moderately 2.361 (0.983, 5.669)
Poorly 3.506 (1.445, 8.502)
Table 4. Prognostic factors used for the multiple Cox’s hazard
regression modeling for adenocarcinoma 
CI, confidence interval.828 H.J. Lee, J. Jo, D.-S. Son, et al.
instances in high- and low-risk groups.
There were 459 SQC patients (of whom 180 displayed early
recurrence and 279 continued to show non-recurrence after
more than 3 yr). We performed a recurrence prediction model
using on the training set of 305 the same methods as on the
ADC patients and then applied the model to the test set of
154. The test set was then divided into two groups, a high-
risk group and a low-risk group with statistically significant
results (with a P value equal to 0.037 in the log-rank test).
The Kaplan-Meier curve for recurrence-free survival is shown
in Fig. 2-2.
DISCUSSION
There has been much recent development in the diagno-
sis and treatment of NSCLC. However, all patients diagnosed
with NSCLC are managed in a uniform manner based on the
stage of the disease, regardless of cell type or other heteroge-
neous characteristics. Neoadjuvant therapy as well as adju-
vant therapy has been applied to the advanced stage patient
but not to the early stage patient with a high-risk for recur-
rence. The purpose of our study is to identify the patients
who are more likely to recur and may benefit from neoadju-
vant or adjuvant therapy. A few studies have investigated a
survival prediction in surgically resected patients with NSCLC
(9, 11-13). However, a postoperative recurrence prediction
has not been studied as much. We focused our predictions
of early recurrence to indicate recurrence within one year after
curative resection. Early recurrence means that a patient might
have a generalized disease before surgery and would benefit
from systemic treatment such as chemotherapy.
We used Cox’s proportional hazard regression models to
see how the factors correlated with the instances of recurrence
after surgery. We analyzed several clinical factors as well as
current pathologic stage systems, which have been regarded
Fig. 2. Recurrence-free survival as a result of prediction in each cell types. Both (A) training set and (B) test set were divided into a high-
and a low-risk groups significantly by our prediction model.
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as the most important factors of deciding the prognosis of
NSCLC. Since many of the clinical factors associated with
NSCLC are related to each other, it is very difficult to separate
one factor from the others or to identify all relationships bet-
ween the factors. So we considered all the factors and tried to
make the most optimal model to accurately predict recurrence.
Our prediction model using the total patients’ information
could distinguish the high-risk group of recurrence from the
low-risk group in the test subgroup (data was not shown).
We specified the data because there are heterogenous groups
in NSCLC. First, we stratified our data according to histolo-
gy. Many studies have investigated the prognostic significance
of different histologies in surgically resected NSCLC patients,
but there still remains controversy (14-16). ADC has differ-
ent characteristics from SQC and their respective recurrence
patterns along with them (16). Forty-two percent of the ADC
patients were female whereas only 4.8% of the SQC patients
were female in this study. The tumor size of the ADC patients
was smaller than that of the SQC patients. Okamoto and his
colleagues demonstrated that the prognosis after complete
resection is different between ADC and SQC (16). In this
study, Fig. 3 shows the differences in recurrence between ADC
and SQC patients. Second, we limited the cases to include
the patients who have recurred within one year and those who
did not detect any recurrence after more than three years. The
early recurrence group has more aggressive features and is a
good candidate for adjuvant treatment. In the ADC patients,
there were more cases of early recurrence (25.3% vs. 23.5%,
ratio to total patients in each cell type) and fewer cases of three
years passing without recurrence (26.5% vs. 36.5%) than for
the patients with SQC. For both ADC and SQC, we could
predict early recurrence in training and test subgroups, and
pathologic TNM stage was the most significant prognostic
factor to determine an early recurrence. Comparing the recur-
rence-free survival curves (Fig. 2), the presence of ADC had
a tendency to more accurately distinguish the high-risk group
from the low-risk group than did SQC. Yokouchi and his
colleagues suggested that in ADC, survival was dominantly
affected by N factor, while in SQC, survival was strongly cor-
related with size, or T factor (17). Fig. 4 shows survival dif-
ference in SQC according to tumor size in this study. We used
the T stage factor in modeling, instead of size, because tumor
size was conceptually included in the T factor. Tumor size
has been proposed to be important in new revised staging
system, and there may be need to study more about it.
We tried to predict recurrence within clinical parameters.
However, there exist several limitations in our retrospective
study. First, we gained the information from the charts, the
radiological reports, and the patients and their family mem-
bers, so it was difficult to get certain information, such as the
performance status and smoking habits. Second, since the
current TNM stage is the most important factor to affect the
prognosis, other factors were ruled out during the modeling
procedure.
In conclusion, we could predict the individual prognosis
of NSCLC patients using only clinical information and pre-
dict early recurrence in each cell type. The prediction model
was reproducible and reliable. However, to improve the com-
pleteness of the prediction model, we need further study in-
cluding more factors like genetic factors as well as biologic
markers.
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